secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2026-06-03T11:03:09+00:00
Accession:  0001628280-26-040038
Event type: leadership
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics appoints Dr. Anna Greka to Board of Directors
---------------------------------------------------------------

- Board increased to seven directors, effective June 15, 2026, with appointment of Anna Greka, M.D., Ph.D. as Class III director.
- Dr. Greka is Professor of Medicine at Harvard Medical School and Mass General Brigham, and holds leadership roles at Broad Institute.
- She will serve on Compensation Committee and Science and Technology Committee, receiving standard non-employee director compensation.
- Standard indemnification agreement entered; no related-party transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026040038/0001628280-26-040038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828026040038/ovid-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-040038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer